Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Initiate tafamidis (80 mg daily) immediately in all patients with ATTR-CM and NYHA class I–III symptoms to reduce cardiovascular mortality and hospitalizations. 1
Disease-Modifying Therapy
TTR Stabilizers (First-Line)
Tafamidis (VYNDAQEL/VYNDAMAX) is the only FDA-approved disease-modifying therapy for ATTR-CM and should be started in patients with NYHA class I–III heart failure symptoms, regardless of wild-type or hereditary subtype. 1
Acoramidis, a second-generation TTR stabilizer, has demonstrated efficacy in reducing mortality and morbidity in the ATTRibute-CM trial and represents an emerging alternative. 2
Do not delay tafamidis initiation while awaiting complete organ assessment—early treatment is essential to prevent irreversible cardiac damage, as therapies are most effective in early-stage disease. 3, 4
TTR Silencers (Investigational for ATTR-CM)
Patisiran and inotersen are FDA-approved only for ATTRv with polyneuropathy, not for ATTR-CM; the FDA declined patisiran approval for cardiac disease despite the APOLLO-B trial showing preservation of functional capacity. 2, 5
Vutrisiran approval for ATTR-CM may be forthcoming based on ongoing phase 3 data. 5
TTR silencers should not be used off-label for ATTR-CM outside of clinical trials until cardiac-specific approval is obtained. 6, 2
Genetic Testing and Family Screening
TTR gene sequencing is mandatory after ATTR-CM diagnosis to distinguish wild-type (ATTRwt) from hereditary (ATTRv) disease, guide family screening, and determine eligibility for genotype-specific therapies. 1
Genetic counseling and cascade screening of first-degree relatives should be initiated when a pathogenic TTR variant is identified, even in the absence of family history, because penetrance is variable. 1
Heart Failure Management
Diuretics (Cornerstone of Therapy)
Loop diuretics are the mainstay of symptom management for volume overload; patients with ATTR-CM rely on high filling pressures to maintain cardiac output, requiring careful titration to avoid hypotension. 3, 4
Mineralocorticoid receptor antagonists may be used cautiously for additional diuresis but require close monitoring of renal function and potassium. 4
Medications to Avoid
ACE inhibitors, ARBs, and ARNi (sacubitril/valsartan) should be avoided or used with extreme caution because their vasodilating effects exacerbate hypotension, especially in the presence of amyloid-associated autonomic dysfunction. 1, 3
Beta-blockers may worsen heart failure symptoms because patients with ATTR-CM depend on heart rate to maintain cardiac output in the setting of restrictive physiology; use only if compelling indications exist (e.g., atrial fibrillation rate control). 1
Digoxin and calcium-channel blockers are contraindicated—they bind amyloid fibrils and cause toxicity even at therapeutic concentrations. 3
Anticoagulation
Anticoagulation is recommended for all ATTR-CM patients with atrial fibrillation, regardless of CHA₂DS₂-VASc score, due to markedly increased thromboembolic risk from atrial stasis and intracardiac thrombus formation. 1, 3
Direct oral anticoagulants (DOACs) are preferred over warfarin for ease of use and lower bleeding risk, unless contraindicated by severe renal dysfunction or mechanical valves. 1
Device Therapy and Advanced Heart Failure Interventions
Implantable Cardioverter-Defibrillators (ICDs)
The benefit of ICDs in ATTR-CM is unclear—a case-control study showed no mortality benefit, and sudden cardiac death is less common than progressive pump failure. 1
ICD implantation should be considered only in highly selected patients with documented ventricular arrhythmias or cardiac arrest survivors, not for primary prevention based on ejection fraction alone. 1
Cardiac Resynchronization Therapy (CRT)
- CRT has not been studied in ATTR-CM with heart failure with reduced ejection fraction (HFrEF) and should not be routinely implanted; the restrictive physiology and conduction abnormalities may limit benefit. 1
Heart Transplantation
Heart transplantation should be considered in select younger patients with ATTRv and isolated cardiac involvement, but wild-type ATTR-CM typically affects older patients who are not transplant candidates. 4
Combined heart-liver transplantation may be considered in ATTRv to eliminate the source of mutant TTR production, though this is reserved for specialized centers. 4
Prognostic Staging and Monitoring
Baseline Staging
Stage patients using NT-proBNP (>3000 pg/mL) and estimated glomerular filtration rate (<45 mL/min/1.73 m²): Stage 1 meets neither threshold, Stage 2 meets one, Stage 3 meets both. 1
Cardiac troponin T (>0.05 ng/mL) is an alternative staging biomarker in ATTRwt-specific systems. 1
Cardiac involvement is the principal prognostic factor—approximately 30% of patients with advanced cardiac disease (Stage 3) die within the first year. 3
Follow-Up Monitoring
Repeat NT-proBNP, troponin, and echocardiography every 3–6 months to assess disease progression and treatment response. 4
Decline in NT-proBNP and stabilization of left ventricular wall thickness or global longitudinal strain indicate favorable response to disease-modifying therapy. 4
Monitor renal function and 24-hour urine protein every 6 months to detect amyloid-related nephropathy. 3, 7
Multiorgan Assessment and Supportive Care
Neurologic Involvement
Screen for peripheral sensorimotor neuropathy (length-dependent axonal and demyelinating features) and autonomic dysfunction (orthostatic hypotension, erectile dysfunction, gastroparesis, chronic diarrhea) at baseline and annually. 3, 7
Midodrine or fludrocortisone may be used for symptomatic orthostatic hypotension. 4
Musculoskeletal Manifestations
- Bilateral carpal tunnel syndrome, lumbar spinal stenosis, and spontaneous biceps tendon rupture are common extracardiac clues; surgical decompression may be required for carpal tunnel syndrome before cardiac symptoms develop. 1, 3
Renal Involvement
- Nephrotic-range proteinuria (>3.5 g/24 h) indicates renal amyloid deposition and portends worse prognosis; manage with diuretics and avoid nephrotoxic agents. 3, 7
Critical Pitfalls to Avoid
Do not assume AL amyloidosis based solely on the presence of a monoclonal protein—over 10% of patients with monoclonal gammopathy have ATTR deposits, and both types can coexist. 1, 3, 7
Do not rely on fat-pad biopsy to monitor treatment response in ATTR-CM—it has only 15% sensitivity for wild-type ATTR and does not reflect cardiac disease burden. 3
Do not postpone disease-modifying therapy while awaiting complete organ assessment—irreversible cardiac damage progresses rapidly, and early treatment improves outcomes. 3, 4
Do not use standard heart failure medications (ACE inhibitors, beta-blockers) reflexively—they are poorly tolerated and may worsen symptoms due to hypotension and reliance on heart rate for cardiac output. 1, 3